An observational study in Pancreatic Cancer, sponsored by RenJi Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-04-06.
Sponsored by RenJi Hospital · Observational
This prospective cohort study is designed to investigate the diagnostic ability and prediction accuracy of pancreatic cancer by radiomics data and clinical data.
In this study, investigators aimed to investigate the diagnostic performance and prediction accuracy of pancreatic cancer by radiomics data and clinical data, which include CT scan, MRI, PET-CT, PET-MR, ultrasound, and clinical data.
3,310 studies on the registry are indexed under Pancreatic Neoplasms; 910 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 200 across 636 observational studies indexed under Pancreatic Neoplasms.
Browse Pancreatic Neoplasms studies →RenJi Hospital is the lead sponsor of 550 studies on the registry; 248 are open to participants now.
Counted across the registry records on this site, refreshed daily.
hospitalized patients with radiology conformed pancreatic tumor
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical diagnosis of pancreatic tumor; Must have CT / MRI / ultrasound data and pathology diagnosis
Exclusion Criteria:
Have other tumors along with pancreatic tumor; Clinical information missing
Patient overall survival
Patient overall survival, from the time of diagnosis of pancreatic tumor to the death of the patient.
Time frame: up to 3 years
Pathology diagnosis
Pathology diagnosis of the patient, such as adenocarcinoma, pancreatic neuroendocrine tumors, intraductal Papillary Mucinous Neoplasm, et al.
Time frame: intraoperative
Progression-free Survival
Patient progression-free survival, the length of time during and after the treatment of the tumor, that a patient lives with the disease but it does not get worse.
Time frame: up to 3 years
This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.